

Halvard Bonig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7223150/publications.pdf>

Version: 2024-02-01

194
papers

5,579
citations

76322

40
h-index

106340

65
g-index

205
all docs

205
docs citations

205
times ranked

8663
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor. <i>Molecular Therapy</i> , 2015, 23, 330-338.	8.2	274
2	Gene therapy with adeno-associated virus vector 5â€“human factor IX in adults with hemophilia B. <i>Blood</i> , 2018, 131, 1022-1031.	1.4	236
3	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	3.5	230
4	Differential Stability of Cell-Free Circulating microRNAs: Implications for Their Utilization as Biomarkers. <i>PLoS ONE</i> , 2013, 8, e75184.	2.5	167
5	Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. <i>Blood</i> , 2008, 111, 3439-3441.	1.4	154
6	CAR T-cells targeting FLT3 have potent activity against FLT3âˆ“ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. <i>Leukemia</i> , 2018, 32, 1168-1179.	7.2	133
7	Spleen Size Is Significantly Influenced by Body Height and Sex: Establishment of Normal Values for Spleen Size at US with a Cohort of 1200 Healthy Individuals. <i>Radiology</i> , 2016, 279, 306-313.	7.3	123
8	Standardization of Good Manufacturing Practiceâ€“compliant production of bone marrowâ€“derived human mesenchymal stromal cells for immunotherapeutic applications. <i>Cytotherapy</i> , 2015, 17, 128-139.	0.7	118
9	The role of G-protein signaling in hematopoietic stem/progenitor cell mobilization. <i>Blood</i> , 2003, 101, 4739-4747.	1.4	107
10	Epigenetic Regulation of Endothelial Lineage Committed Genes in Pro-Angiogenic Hematopoietic and Endothelial Progenitor Cells. <i>Circulation Research</i> , 2011, 109, 1219-1229.	4.5	103
11	Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. <i>Blood</i> , 2013, 121, 1814-1818.	1.4	102
12	RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation. <i>Blood</i> , 2015, 125, 3570-3579.	1.4	93
13	Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2017, 31, 549-562.e11.	16.8	89
14	Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 25-38.	4.2	84
15	Hierarchy of molecular-pathway usage in bone marrow homing and its shift by cytokines. <i>Blood</i> , 2006, 107, 79-86.	1.4	83
16	Concise Review: CXCR4/CXCL12 Signaling in Immature Hematopoiesisâ€“Lessons From Pharmacological and Genetic Models. <i>Stem Cells</i> , 2015, 33, 2391-2399.	3.2	81
17	Discovery and Characterization of an Endogenous CXCR4 Antagonist. <i>Cell Reports</i> , 2015, 11, 737-747.	6.4	80
18	Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. <i>Haematologica</i> , 2016, 101, 985-994.	3.5	78

#	ARTICLE	IF	CITATIONS
19	Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transplantation, 2018, 53, 852-862.	2.4	77
20	Role of Integrin Alpha4 in Drug Resistance of Leukemia. Frontiers in Oncology, 2014, 4, 99.	2.8	75
21	Allogeneic donor peripheral blood stem cell apheresis: prospective comparison of two apheresis systems. Transfusion, 2012, 52, 1137-1145.	1.6	71
22	CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. Gene Therapy, 2021, 28, 560-571.	4.5	70
23	Automatic interface-controlled apheresis collection of stem/progenitor cells: results from an autologous donor validation trial of a novel stem cell apheresis device. Transfusion, 2011, 51, 1321-1330.	1.6	69
24	Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease. Transfusion Medicine and Hemotherapy, 2019, 46, 27-34.	1.6	67
25	PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation. Nature Communications, 2014, 5, 3995.	12.8	60
26	Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors. Molecular Therapy, 2018, 26, 1137-1153.	8.2	53
27	Hematopoietic Progenitor Cells (HPC) from Mobilized Peripheral Blood Display Enhanced Migration and Marrow Homing Compared to Steady-State Bone Marrow HPC. Experimental Hematology, 2007, 35, 326-334.	0.4	52
28	Concurrent Blockade of α 4-Integrin and CXCR4 in Hematopoietic Stem/Progenitor Cell Mobilization. Stem Cells, 2009, 27, 836-837.	3.2	52
29	Mobilization of Hematopoietic Stem/Progenitor Cells: General Principles and Molecular Mechanisms. Methods in Molecular Biology, 2012, 904, 1-14.	0.9	52
30	Autologous cell-based therapy for treatment of large bone defects: from bench to bedside. European Journal of Trauma and Emergency Surgery, 2018, 44, 649-665.	1.7	52
31	Clinical-scale isolation of "minimally manipulated"™ cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease. Cytotherapy, 2014, 16, 1245-1256.	0.7	51
32	Intracoronary bone marrow cell application for terminal heart failure in children. Cardiology in the Young, 2012, 22, 558-563.	0.8	50
33	Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Experimental Hematology, 2009, 37, 402-415.e1.	0.4	49
34	Enumeration of viable CD34+ cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD α , β stem cell enumeration kit. Cytotherapy, 2011, 13, 449-458.	0.7	46
35	Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells. Best Practice and Research in Clinical Haematology, 2011, 24, 331-337.	1.7	46
36	The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the <sc>BAMI</sc> trial. European Journal of Heart Failure, 2017, 19, 1545-1550.	7.1	45

#	ARTICLE	IF	CITATIONS
37	Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation. <i>Cell Reports</i> , 2019, 27, 2022-2028.e3.	6.4	44
38	Cell-Based Therapy by Implanted Human Bone Marrow-Derived Mononuclear Cells Improved Bone Healing of Large Bone Defects in Rats. <i>Tissue Engineering - Part A</i> , 2015, 21, 1565-1578.	3.1	43
39	Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. <i>Blood</i> , 2014, 124, 240-250.	1.4	42
40	Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B. <i>Blood</i> , 2019, 134, 2059-2059.	1.4	42
41	Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression. <i>Haematologica</i> , 2013, 98, 1609-1616.	3.5	41
42	In vitro migration and proliferation (wound healing) potential of mesenchymal stromal cells generated from human CD271+ bone marrow mononuclear cells. <i>Journal of Translational Medicine</i> , 2015, 13, 315.	4.4	41
43	PTX-sensitive signals in bone marrow homing of fetal and adult hematopoietic progenitor cells. <i>Blood</i> , 2004, 104, 2299-2306.	1.4	40
44	Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1830-1842.	1.4	40
45	Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers" results of a dose escalation trial. <i>Journal of Translational Medicine</i> , 2017, 15, 2.	4.4	39
46	Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells. <i>Blood</i> , 2017, 129, 2939-2949.	1.4	39
47	Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems. <i>Transfusion</i> , 2014, 54, 1622-1629.	1.6	38
48	Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT. <i>European Heart Journal</i> , 2016, 37, 1659-1666.	2.2	38
49	Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM" Outcome Report of 92 Patients. <i>Cells</i> , 2019, 8, 1577.	4.1	38
50	On the adaptation of endosteal stem cell niche function in response to stress. <i>Blood</i> , 2009, 114, 3773-3782.	1.4	37
51	Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. <i>Cytotherapy</i> , 2015, 17, 1465-1471.	0.7	37
52	Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4. <i>Frontiers in Immunology</i> , 2020, 11, 2028.	4.8	37
53	Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy. <i>Haematologica</i> , 2016, 101, e153-e156.	3.5	36
54	Pediatric apheresis with a novel apheresis device with electronic interface control. <i>Transfusion</i> , 2013, 53, 761-765.	1.6	34

#	ARTICLE	IF	CITATIONS
55	Characterization of Bone Marrow Mononuclear Cells on Biomaterials for Bone Tissue Engineering <i>In Vitro</i> . <i>BioMed Research International</i> , 2015, 2015, 1-12.	1.9	34
56	Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells. <i>Journal of Clinical Investigation</i> , 2019, 129, 2745-2759.	8.2	32
57	Red blood cell depletion from bone marrow and peripheral blood buffy coat: a comparison of two new and three established technologies. <i>Transfusion</i> , 2015, 55, 1275-1282.	1.6	31
58	Safety and feasibility of cell-based therapy of autologous bone marrow-derived mononuclear cells in plate-stabilized proximal humeral fractures in humans. <i>Journal of Translational Medicine</i> , 2016, 14, 314.	4.4	31
59	Integrin $\alpha 6$ mediates the drug resistance of acute lymphoblastic B-cell leukemia. <i>Blood</i> , 2020, 136, 210-223.	1.4	31
60	Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3957-3968.	7.0	30
61	Clinical-scale isolation of the total <i>Aspergillus fumigatus</i> "reactive" helper cell repertoire for adoptive transfer. <i>Cytotherapy</i> , 2015, 17, 1396-1405.	0.7	30
62	Mesenchymal stromal cells derived from CD271+ bone marrow mononuclear cells exert potent allosuppressive properties. <i>Cytotherapy</i> , 2011, 13, 1193-1204.	0.7	29
63	Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 1141-1143.	2.4	29
64	Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL. <i>Blood</i> , 2016, 128, 1226-1226.	1.4	29
65	Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 137-142.	1.4	29
66	Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1281-1292.	2.0	28
67	Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma "a rationale for tailored supportive care. <i>Supportive Care in Cancer</i> , 2001, 9, 514-521.	2.2	27
68	Biosimilar granulocyte "colony" stimulating factor for healthy donor stem cell mobilization: need we be afraid?. <i>Transfusion</i> , 2015, 55, 430-439.	1.6	27
69	Cancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase. <i>Oncogene</i> , 2019, 38, 4788-4803.	5.9	27
70	Results of a multicenter phase I/II trial of TCR $\alpha\beta$ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 423-430.	2.4	27
71	Generation and Characterization of Erythroid Cells from Human Embryonic Stem Cells and Induced Pluripotent Stem Cells: An Overview. <i>Stem Cells International</i> , 2011, 2011, 1-10.	2.5	26
72	Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte "colony" stimulating factor: safety, efficacy, and graft performance. <i>Transfusion</i> , 2016, 56, 3055-3064.	1.6	24

#	ARTICLE	IF	CITATIONS
73	Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes. <i>Journal of Translational Medicine</i> , 2020, 18, 177.	4.4	24
74	Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1126-1136.	2.4	23
75	ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma. <i>Frontiers in Immunology</i> , 2020, 11, 581468.	4.8	22
76	Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Frontiers in Pediatrics</i> , 2021, 9, 705179.	1.9	22
77	Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion. <i>Cytotherapy</i> , 2014, 16, 835-844.	0.7	21
78	MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO. <i>PLoS Genetics</i> , 2016, 12, e1005946.	3.5	20
79	HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. <i>Blood</i> , 2017, 129, 598-608.	1.4	20
80	ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. <i>Leukemia</i> , 2020, 34, 1907-1923.	7.2	20
81	AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia. <i>Cancer Discovery</i> , 2021, 11, 2924-2943.	9.4	20
82	The osteo-inductive activity of bone-marrow-derived mononuclear cells resides within the CD14+ population and is independent of the CD34+ population. , 2018, 35, 165-177.		20
83	Granulocyte collections: comparison of two apheresis systems. <i>Transfusion</i> , 2013, 53, 3262-3268.	1.6	19
84	Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise. <i>Vox Sanguinis</i> , 2015, 109, 387-393.	1.5	19
85	CD105 Is a Surface Marker for Receptor-Targeted Gene Transfer into Human Long-Term Repopulating Hematopoietic Stem Cells. <i>Stem Cells and Development</i> , 2015, 24, 714-723.	2.1	19
86	Automation of cellular therapy product manufacturing: results of a split validation comparing CD34 selection of peripheral blood stem cell apheresis product with a semi-manual vs. an automatic procedure. <i>Journal of Translational Medicine</i> , 2016, 14, 76.	4.4	19
87	Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells. <i>Cytotherapy</i> , 2018, 20, 532-542.	0.7	19
88	A Proof of the Low Speed Centrifugation Concept in Rodents: New Perspectives for <i>In Vivo</i> Research. <i>Tissue Engineering - Part C: Methods</i> , 2018, 24, 659-670.	2.1	19
89	Hematopoietic alterations in chronic heart failure patients by somatic mutations leading to clonal hematopoiesis. <i>Haematologica</i> , 2020, 105, e328-e332.	3.5	19
90	Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow. <i>Oncotarget</i> , 2016, 7, 70959-70968.	1.8	19

#	ARTICLE	IF	CITATIONS
91	Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak. <i>Experimental Hematology</i> , 2016, 44, 303-314.e1.	0.4	18
92	Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1218.	4.8	18
93	PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1. <i>Oncogenesis</i> , 2021, 10, 42.	4.9	18
94	Epigenetic Modifications and Chromosome Conformations of the Beta Globin Locus throughout Development. <i>Stem Cell Reviews and Reports</i> , 2013, 9, 397-407.	5.6	16
95	Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus. <i>Cytotherapy</i> , 2015, 17, 1139-1151.	0.7	16
96	Defective IL-23/IL-17 Axis Protects p47phox ^{+/+} Mice from Colon Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 44.	4.8	16
97	Risks of leukapheresis and how to manage them – A non-systematic review. <i>Transfusion and Apheresis Science</i> , 2018, 57, 628-634.	1.0	16
98	Mesenchymal stromal cells for osteonecrosis. <i>Journal of Translational Medicine</i> , 2020, 18, 399.	4.4	16
99	Impact of Charged Particle Exposure on Homologous DNA Double-Strand Break Repair in Human Blood-Derived Cells. <i>Frontiers in Oncology</i> , 2015, 5, 250.	2.8	15
100	Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients. <i>Journal of Clinical Apheresis</i> , 2020, 35, 398-405.	1.3	15
101	Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK Cells with Enhanced Antitumor Activity. <i>Cells</i> , 2020, 9, 811.	4.1	15
102	Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site. <i>Journal of Translational Medicine</i> , 2021, 19, 145.	4.4	15
103	Sufficient blood, safe blood: can we have both?. <i>BMC Medicine</i> , 2012, 10, 29.	5.5	13
104	Protein arginine methyltransferase 6 controls erythroid gene expression and differentiation of human CD34 ⁺ progenitor cells. <i>Haematologica</i> , 2018, 103, 18-29.	3.5	13
105	AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years. <i>Blood</i> , 2020, 136, 26-26.	1.4	13
106	Leucodepletion for hyperleucocytosis – first report on a novel technology featuring electronic interphase management. <i>Vox Sanguinis</i> , 2013, 105, 47-53.	1.5	12
107	Variant rs1801157 in the 3'UTR of SDF-1 β Does Not Explain Variability of Healthy-Donor G-CSF Responsiveness. <i>PLoS ONE</i> , 2015, 10, e0121859.	2.5	12
108	Optimization of individualized graft composition: CD3/CD19 depletion combined with CD34 selection for haploidentical transplantation. <i>Transfusion</i> , 2016, 56, 2336-2345.	1.6	12

#	ARTICLE	IF	CITATIONS
109	The p67 laminin receptor identifies human erythroid progenitor and precursor cells and is functionally important for their bone marrow lodgment. <i>Blood</i> , 2006, 108, 1230-1233.	1.4	11
110	Blockade of $\alpha 6$ -Integrin Reveals Diversity in Homing Patterns Among Human, Baboon, and Murine Cells. <i>Stem Cells and Development</i> , 2009, 18, 839-844.	2.1	11
111	Generation and flow cytometric quality control of clinical-scale $\alpha \text{TCR} \pm \beta \text{CD} 19$ -depleted grafts. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 126-135.	1.5	11
112	Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC. <i>Journal of Translational Medicine</i> , 2017, 15, 174.	4.4	11
113	Hematopoietic-Extrinsic Cues Dictate Circadian Redistribution of Mature and Immature Hematopoietic Cells in Blood and Spleen. <i>Cells</i> , 2019, 8, 1033.	4.1	11
114	TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial. <i>Blood</i> , 2016, 128, 389-389.	1.4	11
115	Blood types of current embryonic stem cell lines are not conducive to culturing "universal-donor" red blood cells. <i>Transfusion</i> , 2008, 48, 1039-1040.	1.6	10
116	Functional Consequences of Perturbed CXCL12 Signal Processing: Analyses of Immature Hematopoiesis in GRK6-Deficient Mice. <i>Stem Cells and Development</i> , 2015, 24, 737-746.	2.1	10
117	Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization. <i>Leukemia</i> , 2022, 36, 333-347.	7.2	10
118	Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 366.e1-366.e7.	1.2	10
119	Multi-site evaluation of the BD Stem Cell Enumeration Kit for CD34 + cell enumeration on the BD FACSCanto II and BD FACSCalibur flow cytometers. <i>Cytotherapy</i> , 2014, 16, 1558-1574.	0.7	8
120	A validation protocol and evaluation algorithms to determine compatibility of cell therapy product matrices in microbiological testing. <i>Cell and Tissue Banking</i> , 2015, 16, 311-318.	1.1	8
121	Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long Noncoding RNA PLUT: An Exploratory Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1338-1350.	1.1	8
122	Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan. <i>Frontiers in Pediatrics</i> , 2022, 10, 808103.	1.9	8
123	In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy. <i>Journal of Translational Medicine</i> , 2016, 14, 264.	4.4	7
124	Effects of CD49d-targeted antisense-oligonucleotide on $\alpha 4$ integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies. <i>PLoS ONE</i> , 2017, 12, e0187684.	2.5	7
125	Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma. <i>Cytotherapy</i> , 2018, 20, 839-850.	0.7	7
126	Albumin Modifies Responses to Hematopoietic Stem Cell Mobilizing Agents in Mice. <i>Cells</i> , 2020, 9, 4.	4.1	7

#	ARTICLE	IF	CITATIONS
127	The transcription factor TAL1 and miR-17-92 create a regulatory loop in hematopoiesis. <i>Scientific Reports</i> , 2020, 10, 21438.	3.3	7
128	FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells. <i>Blood</i> , 2018, 132, 903-903.	1.4	7
129	Adjuvant CD49d Blockade Eradicates Chemoresistant ALL. <i>Blood</i> , 2010, 116, 869-869.	1.4	7
130	Validation of a Rapid and Inexpensive Allele-Specific Amplification (ASA)-PCR Genotyping Assay for Vitamin K Antagonist Pharmacogenomics. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 13-19.	3.8	6
131	Update on biosimilars of granulocyte colony-stimulating factor “ when no news is good news. <i>Current Opinion in Hematology</i> , 2016, 23, 61-66.	2.5	6
132	Dopaminergic Modulation of Cognitive Preparation for Overt Reading: Evidence from the Study of Genetic Polymorphisms. <i>Cerebral Cortex</i> , 2016, 26, 1539-1557.	2.9	6
133	Promises and Challenges in Hematopoietic Stem Cell Gene Therapy. <i>Human Gene Therapy</i> , 2017, 28, 782-799.	2.7	6
134	FUSE binding protein 1 (FUBP1) expression is upregulated by T-cell acute lymphocytic leukemia protein 1 (TAL1) and required for efficient erythroid differentiation. <i>PLoS ONE</i> , 2019, 14, e0210515.	2.5	6
135	Reducing the red blood cell transfusion threshold from 8 g/dl to 7 g/dl in acute myeloid leukaemia patients undergoing induction chemotherapy reduces transfusion rates without adversely affecting patient outcome. <i>Vox Sanguinis</i> , 2020, 115, 570-578.	1.5	6
136	The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 3611-3624.	5.2	6
137	Long-term functional impairment of hemopoietic progenitor cells engineered to express the S1 catalytic subunit of pertussis toxin. <i>Experimental Hematology</i> , 2005, 33, 689-698.	0.4	5
138	A novel association between relaxin receptor polymorphism and hematopoietic stem cell yield after mobilization. <i>PLoS ONE</i> , 2017, 12, e0179986.	2.5	5
139	Mobilized peripheral blood stem cell apheresis via Hickman catheter in pediatric patients. <i>Transfusion</i> , 2019, 59, 1061-1068.	1.6	5
140	Introduction of principles of blood management to healthy donor bone marrow harvesting. <i>Vox Sanguinis</i> , 2020, 115, 802-812.	1.5	5
141	Oral Small Molecule Inhibitor of VLA-4 Overcomes Adhesion Mediated Chemotherapy Resistance of Acute Myeloid Leukemia (AML) Blasts in Vitro, without Impairment of Normal Blood Cell Recovery When Combined with Chemotherapy in Vivo. <i>Blood</i> , 2008, 112, 858-858.	1.4	5
142	Release of the Soluble Interleukin-6 Receptor from Human T-Cells. <i>Immunological Investigations</i> , 1998, 27, 47-55.	2.0	4
143	Response: More about multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors. <i>Blood</i> , 2008, 112, 209-210.	1.4	4
144	Asystole during stem cell apheresis in a young healthy female volunteer donor. <i>Transfusion</i> , 2011, 51, 1594-1595.	1.6	4

#	ARTICLE	IF	CITATIONS
145	The Challenges of Autologous Cell Therapy: Systemic Anti-thrombotic Therapies Interfering with Serum Coagulation May Disable Autologous Serum-Containing Cell Products for Therapeutical Use. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 644-650.	2.4	4
146	Hematopoietic transcription factors and differential cofactor binding regulate <i>PRKACB</i> isoform expression. <i>Oncotarget</i> , 2017, 8, 71685-71698.	1.8	4
147	Adaptive Immunity and Pathogenesis of Diabetes: Insights Provided by the α 5 β 1 Integrin Deficient NOD Mouse. <i>Cells</i> , 2020, 9, 2597.	4.1	4
148	CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transplants: Mostly Efficient, but not Robust. <i>Clinical Hematology International</i> , 2021, 3, 103.	1.7	4
149	Phase II study of haploidentical stem cell transplantation using ex vivo photodepletion of donor lymphocyte infusions to eliminate anti-host reactivity results in low relapse rates and high survival rates: Final 2 year follow-up. <i>Cytotherapy</i> , 2018, 20, S10-S11.	0.7	3
150	ABO incompatible graft management in pediatric transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 84-90.	2.4	3
151	Generation and validation of a formula to calculate hemoglobin loss on a cohort of healthy adults subjected to controlled blood loss. <i>Journal of Translational Medicine</i> , 2021, 19, 116.	4.4	3
152	Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing. <i>Blood</i> , 2021, 138, 814-817.	1.4	3
153	Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy. <i>Blood</i> , 2018, 132, 3476-3476.	1.4	3
154	Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning. <i>Blood</i> , 2018, 132, 604-604.	1.4	3
155	Development and Exploitation of a Fully Human and Modular Organotypic Bone Marrow Niche Model to Study the Role of Stroma-Produced Factors in Human MDS. <i>Blood</i> , 2020, 136, 23-23.	1.4	3
156	The Small Molecule Inhibitor of VLA4 TBC3486 Sensitizes Resistant ALL to Chemotherapy. <i>Blood</i> , 2012, 120, 1500-1500.	1.4	3
157	Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin α 6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10. <i>Blood</i> , 2015, 126, 2525-2525.	1.4	3
158	Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen. <i>Blood</i> , 2015, 126, 4391-4391.	1.4	3
159	Feasibility of CD3/CD19 depletion of a bone marrow graft. <i>Cytotherapy</i> , 2016, 18, 1345-1347.	0.7	2
160	Special Clinical Scenarios: Hyperleukocytosis. <i>Hematologic Malignancies</i> , 2021, , 267-273.	0.2	2
161	Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations. <i>Journal of Translational Medicine</i> , 2021, 19, 190.	4.4	2
162	Potent Stem Cell Mobilization with the Novel CXCR4 Antagonist POL6326 - Results of a Phase IIa Dose Escalation Study in Comparison to G-CSF. <i>Blood</i> , 2015, 126, 511-511.	1.4	2

#	ARTICLE	IF	CITATIONS
163	Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia. <i>Frontiers in Pediatrics</i> , 2021, 9, 784377.	1.9	2
164	A New Perspective for Bone Tissue Engineering: Human Mesenchymal Stromal Cells Well-Survive Cryopreservation on Î²-TCP Scaffold and Show Increased Ability for Osteogenic Differentiation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1425.	4.1	2
165	Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation. <i>Journal of Translational Medicine</i> , 2022, 20, 121.	4.4	2
166	Optimization and validation of processes related to the GMP compliant manufacture of genetically modified CAR expressing NK-92 cells. <i>Cytotherapy</i> , 2015, 17, S25.	0.7	1
167	Progressive multifocal leukoencephalopathy after daratumumab in a patient post allo-HCT successfully treated with JC-virus specific donor lymphocytes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e280.	0.4	1
168	A Single Dose of Donor Lymphocytes Depleted of Alloreactive T Cells (ATIR101) after Haploidentical HSCT Is Well-Tolerated and Efficacious: Pooled Analysis of Two Phase II Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S202.	2.0	1
169	Single Center Real Life Experiences in the Treatment of Pediatric, Adolescent and Young Adult ALL Patients Using Commercially Available CAR-T-Cells in Germany – Susceptibility to Bridging Chemotherapy Predicts Response.. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S262.	2.0	1
170	Depletion of CD45RA+ T cells: Advantages and disadvantages of different purification methods. <i>Journal of Immunological Methods</i> , 2021, 492, 112960.	1.4	1
171	Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation "MSC-FFM": Treatment Results for 92 Consecutive Patients. <i>Blood</i> , 2018, 132, 603-603.	1.4	1
172	Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies. <i>Blood</i> , 2018, 132, 120-120.	1.4	1
173	Hematopoietic Stem/Progenitor Cells (HSPC) Mobilization Parameters in Patients Chronically Treated with the CD49d Blocking Antibody Natalizumab.. <i>Blood</i> , 2007, 110, 177-177.	1.4	1
174	Insights into the Biology of Mobilized Cells through Innovative Treatment Schedules of the CXCR4 Antagonist AMD3100.. <i>Blood</i> , 2007, 110, 2229-2229.	1.4	1
175	Preclinical Evaluation of Tysabri as a Novel Adjuvant Therapy against Drug Resistant B-ALL.. <i>Blood</i> , 2009, 114, 3089-3089.	1.4	1
176	Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling. <i>Blood</i> , 2016, 128, 2648-2648.	1.4	1
177	Donor-intrinsic variables determine mobilization efficiency: analyses from a cohort of sixty twice-mobilized stem cell donors. <i>Journal of Translational Medicine</i> , 2020, 18, 487.	4.4	1
178	Vagrant Stem Cells Draft Their Gene Companions. <i>Cell Stem Cell</i> , 2010, 7, 547-548.	11.1	0
179	In reply. <i>Transfusion</i> , 2014, 54, 2585-2586.	1.6	0
180	Establishment of a GMP-compliant mesenchymal stromal cell bank from pooled bone marrow mononuclear cells of eight –third-party– healthy donors: clinical evidence of safety and efficacy. <i>Cytotherapy</i> , 2015, 17, S12.	0.7	0

#	ARTICLE	IF	CITATIONS
181	The role of Wnt/b-catenin-signalling for cell fate decision in megakaryopoiesis of the haematopoietic system. <i>Experimental Hematology</i> , 2017, 53, S57.	0.4	0
182	Disturbed immature hematopoiesis in mice with hematopoietic-specific wave complex deficiency. <i>Experimental Hematology</i> , 2017, 53, S58.	0.4	0
183	Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Stem Cell Transplantations. <i>Experimental Hematology</i> , 2018, 64, S62.	0.4	0
184	Modest and nonessential roles of the endocannabinoid system in immature hematopoiesis of mice. <i>Experimental Hematology</i> , 2019, 78, 35-45.	0.4	0
185	THE ASSOCIATION OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL WITH CHRONIC ISCHEMIC HEART FAILURE. <i>Experimental Hematology</i> , 2019, 76, S64-S65.	0.4	0
186	A single dose of donor lymphocytes depleted of anti-host reactive T cells (ATIR101) following T-cell-depleted haploidentical HSCT is safe and efficacious. <i>Cytotherapy</i> , 2019, 21, S20-S21.	0.7	0
187	Characterizing the Motility of Chemotherapeutics-Treated Acute Lymphoblastic Leukemia Cells by Time-Lapse Imaging. <i>Cells</i> , 2020, 9, 1470.	4.1	0
188	Gi Protein Signals Are Required for BM Homing of Hemopoietic Progenitor Cells, and Cooperate with Alpha4-Intergrin and Endothelial Selectins.. <i>Blood</i> , 2004, 104, 2183-2183.	1.4	0
189	GRK6 Ablation Is Associated with Surprisingly Modest Effects on Immature Hematopoiesis. <i>Blood</i> , 2011, 118, 2381-2381.	1.4	0
190	Rapid and Potent Mobilization of Murine Hematopoietic Stem and Progenitor Cells by the Novel CXCR4 Antagonist POL5551. <i>Blood</i> , 2012, 120, 4100-4100.	1.4	0
191	Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial. <i>Blood</i> , 2016, 128, 2172-2172.	1.4	0
192	Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors. <i>Blood</i> , 2019, 134, 592-592.	1.4	0
193	Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy. <i>Blood</i> , 2019, 134, 2623-2623.	1.4	0
194	Implication of ICOSLG on Relapse in Infant T(4;11) Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3481-3481.	1.4	0